WHEN TO CONSIDER XCOPRI
Are your epilepsy patients still experiencing seizures? It may be time to consider XCOPRI
AN ESTABLISHED ANTI-SEIZURE MEDICATION (ASM) DELIVERING ON THE POSSIBILITY OF ZERO1
hidden
#1
prescribed by Epileptologists for new branded ASMs2*
0
patients
on XCOPRI2†
0
prescriptions written to date for XCOPRI2†
3+
years since
FDA approval1
0 XCOPRI® (cenobamate tablets) CV prescriptions have been written to date for approximately 0 patients2†
ZERO
As many as 1 in 5 patients experienced
ZERO seizures during the maintenance
phase when taking XCOPRI1
Flexible, once-daily dosing to take patients through their treatment journey1
MOA
XCOPRI is thought to work via a multimodal mechanism of action1*
XCOPRI has been shown to reduce repetitive neuronal firing by inhibiting voltage-gated sodium currents, including inhibiting the component of the sodium current1

XCOPRI is also a positive allosteric modulator of the y-aminobutyric acid (GABAA) ion channel1

XCOPRI IN ACTION
See how XCOPRI partial-onset seizure treatment may fit into your patients’ lives